This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Oxatomide is an antihistamine indicated in the treatment and prevention of allergic symptoms.
- Generic Name
- Oxatomide
- DrugBank Accession Number
- DB12877
- Background
Oxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Oxatomide (DB12877)
- Weight
- Average: 426.564
Monoisotopic: 426.241961602 - Chemical Formula
- C27H30N4O
- Synonyms
- Oxatomida
- Oxatomide
- Oxatomidum
- External IDs
- KW-4354
- McN-JR 35443
- R 35 443
- R 35,443
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category Oxatomide H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Oxatomide. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Oxatomide. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Oxatomide. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Oxatomide. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Oxatomide. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Oxatomide. Amifampridine The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Oxatomide. Amiodarone The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Amisulpride. Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Oxatomide. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Take with food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Celtect / Tinset
Categories
- ATC Codes
- R06AE06 — Oxatomide
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Benzimidazoles / N-alkylpiperazines / Aralkylamines / N-substituted imidazoles / Heteroaromatic compounds / Ureas / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds show 2 more
- Substituents
- 1,4-diazinane / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzimidazole / Diphenylmethane / Heteroaromatic compound / Hydrocarbon derivative show 14 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- J31IL9Z2EE
- CAS number
- 60607-34-3
- InChI Key
- BAINIUMDFURPJM-UHFFFAOYSA-N
- InChI
- InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
- IUPAC Name
- 1-{3-[4-(diphenylmethyl)piperazin-1-yl]propyl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
- SMILES
- O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
References
- General References
- AIFA Product Information: Tinset (oxatomide) for oral and topical use [Link]
- External Links
- Human Metabolome Database
- HMDB0240225
- KEGG Drug
- D01773
- PubChem Compound
- 4615
- PubChem Substance
- 347829033
- ChemSpider
- 4454
- BindingDB
- 76863
- 54236
- ChEBI
- 31943
- ChEMBL
- CHEMBL13828
- ZINC
- ZINC000019632896
- PharmGKB
- PA163522137
- Wikipedia
- Oxatomide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Duchenne Muscular Dystrophy (DMD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Gel Topical 5 % Solution / drops Oral 0.25 % Solution / drops Oral 25 MG/ML Suspension Oral 25 mg/ml Tablet Oral 30 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0393 mg/mL ALOGPS logP 4.71 ALOGPS logP 4.62 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 12.92 Chemaxon pKa (Strongest Basic) 8.01 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 38.82 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 130.94 m3·mol-1 Chemaxon Polarizability 48.79 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 21, 2016 00:57 / Updated at June 12, 2021 10:54